Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand

INTRODUCTION: Diabetes treatment has incurred financial burden. We examined the cost–utility of adding dapagliflozin to the standard treatment for treating type 2 diabetes (T2DM) with cardiovascular risk in a Thai context. METHODS: A two-part model, decision tree and Markov models, was developed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Deerochanawong, Chaicharn, Vareesangthip, Kriengsak, Piyayotai, Dilok, Thongsuk, Dittaya, Pojchaijongdee, Nuch, Permsuwan, Unchalee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266922/
https://www.ncbi.nlm.nih.gov/pubmed/34106450
http://dx.doi.org/10.1007/s13300-021-01088-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266922/
https://www.ncbi.nlm.nih.gov/pubmed/34106450
http://dx.doi.org/10.1007/s13300-021-01088-w

Ejemplares similares